Image source: The Motley Fool.
Tencent Holdings (OTCMKTS:TCEHY) Q2 2018 Earnings Conference CallAug. 15, 2018 8:00 a.m. ET
Prepared Remarks Questions and Answers Call Participants
Thank you for standing by, and welcome to the Tencent Holdings Limited 2018 second-quarter and interim results conference call. [Operator instructions] I must advise you that this conference is being recorded today. I would now like to hand the conference over to your host today, Ms. Jane Yip from Tencent.
Please go ahead, Ms. Yip.
Jane Yip — Investor Relations
Thank you. Good evening. Welcome to our 2018 second-quarter and interim results conference call. I’m Jane Yip from the IR team of Tencent.
Before we start the presentation, we would like to remind you that it includes forward-looking statements, which are underlined by a number of risks and uncertainties and may not be realized in the future for various reasons. Information about general market conditions is coming from a variety of sources outside of Tencent. This presentation also contains some unaudited non-GAAP financial measures that should be considered in addition to but not as a substitute for measures of the company’s financial performance prepared in accordance with IFRS. For a detailed discussion of risk factors and non-GAAP measures, please refer to our disclosure documents on the IR section of our website.
Hot Medical Stocks To Buy For 2021: ProQR Therapeutics N.V.(PRQR)
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of Ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA). The Company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. The Company’s product candidates include QR-010 and QR-110. The Company is focusing on developing QRX- 911, QRX- 021, QRX- 313 for Epidermolysis bullosa, QRX- 704 for Huntington’s disease, QRX- 812, QRX- 411 for Usher syndrome, QRX- 504 for Fuchs, QRX- 604 for Friedreich’s ataxia and QRX- 203 for Alzheimer’s disease.
The Company’s lead product candidate, QR-010, is an RNA-based oligonucleotide. QR-010 is designed to address the underlying cause of the disease by repairing the mRNA defect encoded by the delta-F508 mutation in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene of CF patients. The delta-F508 mutation is a deletion of over three of the coding base pairs or nucleotides, in the CFTR gene, which results in the production of a misfolded CFTR protein that does not function normally. QR-110 is designed to bind to the mutated location in the pre-mRNA, thereby leading to normally spliced or wild-type mRNA, which could produce wild-type or normal protein. QR-110 is designed to be administered through intravitreal injections in the eye.
The Company’s product candidate, QR-110, is an oligonucleotide. QR-110 is designed to treat the disease by repairing the underlying cause in the mRNA, which results in the production of wi! ld-type centrosomal protein 290 (CEP290 protein). QR-110 is designed to bind to the mutated location in the pre-mRNA, masking the cryptic splice site, thereby leading to normally spliced or wild-type mRNA, which could produce wild-type or normal protein. QR-110 is designed to be administered through intravitreal injections in the eye.
The Company competes with Vertex Pharmaceuticals Inc., Novartis International AG, Hoffmann-LaRoche Ltd., Pfizer Inc., Galapagos, AbbVie Laboratories, Shire, Sanofi, Bayer AG, Proteostasis, Corbus Pharmaceuticals, Nivalis and Gilead.
- [By Cory Renauer]
ProQR (NASDAQ:PRQR) is developing QR-110 to treat patients with a mutation on the same gene as EDIT-101 but in a much different manner. QR-110 would require repeat injections right in the eyes to help a mutated gene produce functional copies of the CEP290 protein, while EDIT-101 is designed to repair the gene and provide a permanent solution with a single treatment.
- [By Keith Speights]
Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) were up 16% as of 3:48 p.m. EDT on Monday. ProQR didn’t report any new announcements, but the biotech’s update last Wednesday from a phase 1/2 clinical study — of RNA medicine QR-110, in treating Leber congenital amaurosis type 10 (LCA10) — still had investors fired up.
Hot Medical Stocks To Buy For 2021: Advent Claymore Convertible Securities and Income Fund(AVK)
Advent Claymore Convertible Securities and Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund’s investment objective is to provide total return through a combination of capital appreciation and current income. The Fund will invest at least 80% of its managed assets in a diversified portfolio of convertible securities and non-convertible income securities. It will invest at least 60% of its managed assets in convertible securities and up to 40% of its managed assets in lower-grade, non-convertible income securities.
The Fund invests in various sectors, including insurance, health care products and services, electronic equipment and components, pharmaceuticals, aluminum, steel and other metals, financial services, telecommunications, utilities – gas and electric, banking and finance and oil and gas. Advent Capital Management, LLC serves as the Fund’s investment advisor.
- [By Max Byerly]
Saba Capital Management L.P. lessened its stake in Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) by 91.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,101 shares of the investment management company’s stock after selling 255,542 shares during the period. Saba Capital Management L.P. owned 0.11% of Advent Claymore Convertible Sec & Inc Fd worth $384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
- [By Ethan Ryder]
Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) insider Tracy V. Maitland purchased 50,000 shares of Advent Claymore Convertible Sec & Inc Fd stock in a transaction dated Thursday, September 6th. The shares were acquired at an average cost of $15.68 per share, for a total transaction of $784,000.00. Following the completion of the transaction, the insider now owns 12,000 shares of the company’s stock, valued at approximately $188,160. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
- [By Ethan Ryder]
Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) VP Tony Huang bought 2,066 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was acquired at an average cost of $15.66 per share, for a total transaction of $32,353.56. Following the completion of the acquisition, the vice president now directly owns 7,100 shares in the company, valued at $111,186. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Hot Medical Stocks To Buy For 2021: First Connecticut Bancorp, Inc.(FBNK)
First Connecticut Bancorp, Inc. operates as the holding company for Farmington Bank that provides various commercial and consumer banking services to businesses, individuals, and governments in the United States. The company offers various deposit instruments, including checking, savings, money market savings, and negotiable order of withdrawal accounts, as well as fixed-rate time deposits. It also provides one-to-four family residential real estate loans; commercial real estate loans; construction loans, such as commercial construction loans and real estate subdivision development loans to developers, licensed contractors, and builders for the construction and development of commercial real estate projects and residential properties, as well as loans to individuals and contractors for the construction and acquisition of personal residences; and commercial loans comprising term loans, revolving lines of credit for working capital needs, equipment lines of credit to facilitate the purchase of equipment, and letters of credit. In addition, the company offers home equity loans and home equity lines of credit secured by owner-occupied one-to-four family residences; and consumer loans, including installment, demand, revolving credit, and collateral loans, as well as resort loans. Further, it provides wealth management services. As of May 20, 2015, the company operated 22 branch locations in central Connecticut. It also operates four limited services offices, two stand-alone ATM facilities, and one commercial loan office. First Connecticut Bancorp, Inc. was founded in 1851 and is based in Farmington, Connecticut.
- [By Shane Hupp]
Get a free copy of the Zacks research report on First Connecticut Bancorp (FBNK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
Spark Investment Management LLC decreased its position in First Connecticut Bancorp Inc (NASDAQ:FBNK) by 20.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,400 shares of the bank’s stock after selling 2,700 shares during the period. Spark Investment Management LLC owned 0.07% of First Connecticut Bancorp worth $318,000 at the end of the most recent quarter.
- [By Shane Hupp]
Wells Fargo & Company MN boosted its holdings in shares of First Connecticut Bancorp Inc (NASDAQ:FBNK) by 8.6% in the first quarter, Holdings Channel reports. The institutional investor owned 148,333 shares of the bank’s stock after purchasing an additional 11,719 shares during the quarter. Wells Fargo & Company MN’s holdings in First Connecticut Bancorp were worth $3,798,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Jordan Wathen]
Shares of First Connecticut Bancorp Inc. (NASDAQ:FBNK) are soaring today, rising by more than 19% as of 11:00 a.m. EDT on news of an acquisition. The parent company ofFarmington Bank will be acquired by People’s United Financial (NASDAQ:PBCT) in an all-stock transaction valued at $544 million.